These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

487 related items for PubMed ID: 21592159

  • 1. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
    Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.
    J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S, Zarei T, Zahedi Z, Karimi M.
    Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
    [Abstract] [Full Text] [Related]

  • 4. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
    Vichinsky E, Pakbaz Z, Onyekwere O, Porter J, Swerdlow P, Coates T, Lane P, Files B, Mueller BU, Coïc L, Forni GL, Fischer R, Marks P, Rofail D, Abetz L, Baladi JF.
    Acta Haematol; 2008 Jun; 119(3):133-41. PubMed ID: 18408362
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
    Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Duh MS.
    Pediatr Blood Cancer; 2013 May; 60(5):828-35. PubMed ID: 23335275
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM, Fisher SA, Madgwick KV, Trivella M, Hopewell S, Doree C, Estcourt LJ.
    Cochrane Database Syst Rev; 2018 May 08; 5(5):CD012349. PubMed ID: 29737522
    [Abstract] [Full Text] [Related]

  • 13. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
    McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P, Dickson R, Dundar Y, Greenhalgh J, Modell B, Olujohungbe A, Telfer P, Walley T.
    Health Technol Assess; 2009 Jan 08; 13(1):iii-iv, ix-xi, 1-121. PubMed ID: 19068191
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.
    Karnon J, Tolley K, Vieira J, Chandiwana D.
    Clin Drug Investig; 2012 Dec 08; 32(12):805-15. PubMed ID: 23026844
    [Abstract] [Full Text] [Related]

  • 16. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.
    Vekeman F, Sasane M, Cheng WY, Ramanakumar AV, Fortier J, Qiu Y, Duh MS, Paley C, Adams-Graves P.
    J Med Econ; 2016 Dec 08; 19(3):292-303. PubMed ID: 26618853
    [Abstract] [Full Text] [Related]

  • 17. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep 08; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.
    Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane P, Mathias L, Porter J, Tebbi C, Wilson F, Griffel L, Deng W, Giannone V, Coates T.
    Br J Haematol; 2011 Aug 08; 154(3):387-97. PubMed ID: 21592110
    [Abstract] [Full Text] [Related]

  • 19. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
    Meerpohl JJ, Antes G, Rücker G, Fleeman N, Niemeyer C, Bassler D.
    Cochrane Database Syst Rev; 2010 Aug 04; (8):CD007477. PubMed ID: 20687088
    [Abstract] [Full Text] [Related]

  • 20. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.
    Ann Hematol; 2013 Jan 04; 92(2):191-8. PubMed ID: 23073603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.